These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 15875093)

  • 1. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
    Kanis JA; Barton IP; Johnell O
    Osteoporos Int; 2005 May; 16(5):475-82. PubMed ID: 15875093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
    Roux C; Goldstein JL; Zhou X; Klemes A; Lindsay R
    Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fracture risk remains reduced one year after discontinuation of risedronate.
    Watts NB; Chines A; Olszynski WP; McKeever CD; McClung MR; Zhou X; Grauer A
    Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
    Watts NB; Geusens P; Barton IP; Felsenberg D
    J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
    Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
    J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
    Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.
    Adachi JD; Rizzoli R; Boonen S; Li Z; Meredith MP; Chesnut CH
    Aging Clin Exp Res; 2005 Apr; 17(2):150-6. PubMed ID: 15977464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
    Clemmesen B; Ravn P; Zegels B; Taquet AN; Christiansen C; Reginster JY
    Osteoporos Int; 1997; 7(5):488-95. PubMed ID: 9425508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
    Reginster J; Minne HW; Sorensen OH; Hooper M; Roux C; Brandi ML; Lund B; Ethgen D; Pack S; Roumagnac I; Eastell R
    Osteoporos Int; 2000; 11(1):83-91. PubMed ID: 10663363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
    Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
    Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.
    Watts NB; Lindsay R; Li Z; Kasibhatla C; Brown J
    Osteoporos Int; 2003 Jun; 14(5):437-41. PubMed ID: 12730756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
    Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
    Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
    Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
    Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risedronate prevents new vertebral fractures in postmenopausal women at high risk.
    Watts NB; Josse RG; Hamdy RC; Hughes RA; Manhart MD; Barton I; Calligeros D; Felsenberg D
    J Clin Endocrinol Metab; 2003 Feb; 88(2):542-9. PubMed ID: 12574177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo.
    Watts NB; Brown JP; Cline G
    J Clin Densitom; 2010; 13(1):56-62. PubMed ID: 19942469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.